The Latest Progress in the Application of Telitacicept in Autoimmune Diseases

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2024 Dec 12

PMID 39664967

Authors

Baocheng Liu

Yaqi Zhao

Dongxia Liu

Xinya Li

Zhenzhen Ma

Qingrui Yang

Affiliations

Soon will be listed here.

Abstract

Introduction: Humoral immunity plays a key role in the pathogenesis of autoimmune diseases, and B-lymphocyte activating factor (BAFF) and a proliferation-inducing ligand (APRIL) are essential for the maintenance of B-lymphocyte reservoirs and humoral immunity. In March 2021, telitacicept, the world's first dual target three-channel biologic, was approved in China for the treatment of SLE and is currently in clinical trials exploring multiple indications for other autoimmune diseases.

Areas Covered: This article summarizes the mechanism of action, pharmacokinetics, and clinical efficacy of telitacicept for the treatment of multiple autoimmune diseases.

Expert Opinion: So far, the efficacy and safety of telitacicept in autoimmune diseases have been fully demonstrated in clinical practice. There are still many unresolved issues regarding the timing of initiation and discontinuation, still needs to be evaluated in future studies.

References

Gordon C, Wofsy D, Wax S, Li Y, Rossi C, Isenberg D . Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL. Arthritis Rheumatol. 2016; 69(1):122-130. PMC: 6681010. DOI: 10.1002/art.39809. View

Chen J, Zhan J, Liang S, Wang X, Lin C, Xu Q . A patient with refractory proliferative lupus nephritis treated with telitacicept: A case report. Int J Rheum Dis. 2023; 26(7):1417-1421. DOI: 10.1111/1756-185X.14752. View

Mockel T, Basta F, Weinmann-Menke J, Schwarting A . B cell activating factor (BAFF): Structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE). Autoimmun Rev. 2020; 20(2):102736. DOI: 10.1016/j.autrev.2020.102736. View

Connick P, Kolappan M, Crawley C, Webber D, Patani R, Michell A . Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol. 2012; 11(2):150-6. PMC: 3279697. DOI: 10.1016/S1474-4422(11)70305-2. View

Chen X, Zhao Q, Hou Y, Jiang J, Zhong W, Wang W . Pharmacokinetics, pharmacodynamics, short term efficacy and safety of RCT-18, a novel BLyS/APRIL fusion protein, in patients with rheumatoid arthritis. Br J Clin Pharmacol. 2016; 82(1):41-52. PMC: 4917793. DOI: 10.1111/bcp.12908. View

Gilhus N . Myasthenia Gravis. N Engl J Med. 2016; 375(26):2570-2581. DOI: 10.1056/NEJMra1602678. View

Zhang L, Li P, Song S, Liu Y, Wang Q, Chang Y . Comparative efficacy of TACI-Ig with TNF-alpha inhibitor and methotrexate in DBA/1 mice with collagen-induced arthritis. Eur J Pharmacol. 2013; 708(1-3):113-23. DOI: 10.1016/j.ejphar.2013.02.025. View

Shelly S, Klein C, Dyck P, Paul P, Mauermann M, Berini S . Neurofascin-155 Immunoglobulin Subtypes: Clinicopathologic Associations and Neurologic Outcomes. Neurology. 2021; 97(24):e2392-e2403. PMC: 8673722. DOI: 10.1212/WNL.0000000000012932. View

Ruggenenti P, Debiec H, Ruggiero B, Chianca A, Pelle T, Gaspari F . Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy. J Am Soc Nephrol. 2015; 26(10):2545-58. PMC: 4587688. DOI: 10.1681/ASN.2014070640. View

10.

Xu D, Fang J, Zhang S, Huang C, Huang C, Qin L . Efficacy and safety of telitacicept in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial. Rheumatology (Oxford). 2023; 63(3):698-705. DOI: 10.1093/rheumatology/kead265. View

11.

Xin G, Shi W, Xu L, Su Y, Yan L, Li K . Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features. J Nephrol. 2012; 26(4):683-90. DOI: 10.5301/jn.5000218. View

12.

Dhillon S . Telitacicept: First Approval. Drugs. 2021; 81(14):1671-1675. DOI: 10.1007/s40265-021-01591-1. View

13.

Ding J, Cai Y, Deng Y, Jiang X, Gao M, Lin Y . Telitacicept Following Plasma Exchange in the Treatment of Subjects With Recurrent NMOSD: Study Protocol for a Single-Center, Single-Arm, Open-Label Study. Front Neurol. 2021; 12:596791. PMC: 8044936. DOI: 10.3389/fneur.2021.596791. View

14.

Garcia-Carmona Y, Cols M, Ting A, Radigan L, Yuk F, Zhang L . Differential induction of plasma cells by isoforms of human TACI. Blood. 2015; 125(11):1749-58. PMC: 4357582. DOI: 10.1182/blood-2014-05-575845. View

15.

Harvey P, Gordon C . B-cell targeted therapies in systemic lupus erythematosus: successes and challenges. BioDrugs. 2013; 27(2):85-95. DOI: 10.1007/s40259-013-0015-8. View

16.

Cai J, Gao D, Liu D, Liu Z . Telitacicept for autoimmune nephropathy. Front Immunol. 2023; 14:1169084. PMC: 10277628. DOI: 10.3389/fimmu.2023.1169084. View

17.

Ren Y, Chen S, Yang H . Case Report: Telitacicept in treating a patient with NF155+ autoimmune nodopathy: a successful attempt to manage recurrent elevated sero-anti-NF155 antibodies. Front Immunol. 2023; 14:1279808. PMC: 10642300. DOI: 10.3389/fimmu.2023.1279808. View

18.

Chen R, Fu R, Lin Z, Huang C, Huang W . The efficacy and safety of telitacicept for the treatment of systemic lupus erythematosus: a real life observational study. Lupus. 2022; 32(1):94-100. DOI: 10.1177/09612033221141253. View

19.

Leblanc-Trudeau C, Masetto A, Bocti C . Progressive multifocal leukoencephalopathy associated with belimumab in a patient with systemic lupus erythematosus. J Rheumatol. 2015; 42(3):551-2. DOI: 10.3899/jrheum.140577. View

20.

Cai S, Hu Z, Chen Y, Chen Y, Ming B, Gao R . BLyS/APRIL dual inhibition for IgG4-RD: a prospective single-arm clinical trial of telitacicept. Ann Rheum Dis. 2023; 82(6):881-883. PMC: 10313947. DOI: 10.1136/ard-2022-223529. View